| ¿µ¹® | cystic fibrosis | ÇÑ±Û | ³¶¼º¼¶À¯Áõ |
|---|---|---|---|
| ¼³¸í | À¯Àüº´ÀÇ Çϳª·Î ¶¡»ù, ±â°üÁö¿¡¼ Á¡¾×À» ºÐºñÇÏ´Â »ù, ÀÌÀÚµîÀÇ ¿ÜºÐºñ»ù(¸ö ¹ÛÀ¸·Î ¾×ü¸¦ ºÐºñÇÏ´Â »ù. ³»ºÐºñ»ùÀ» Á¦¿ÜÇÑ ¸ðµç »ùÀ» À̸¥´Ù)ÀÇ ÀÌ»óÀ» Ư¡À¸·Î ÇÏ´Â º´ÀÌ´Ù. Áß¿äÇÑ º´ÀûÀÎ º¯È´Â ÁÖ·Î ±â°üÁö¿¡¼ Á¡¾×À» ºÐºñÇÏ´Â ºÐºñ»ù¿¡¼ Áö³ªÄ¡°Ô Á¡µµ°¡ ³ôÀº Á¡¾×ÀÌ ºÐºñµÇ¾î ±â°üÁö¸¦ ¸·¾Æ È£ÈíÀå¾Ö¸¦ ÀÏÀ¸Å°´Â ÆóÀÇ º´ÅÍÀ̸ç, ¶¡¿¡¼ °úµµÇÑ ÀüÇØÁú ƯÈ÷ ¿°È³ªÆ®·ý(NaCl)ÀÌ ºÐºñµÇ¾î ¸ö¿¡ ÀüÇØÁúÀÌ ºÎÁ·ÇÏ°Ô µÈ´Ù. ¶Ç ÀÌÀÚÀÇ ¼ÒȾ×À» ºÐºñÇÏ´Â ºÐºñ»ùÀÇ ÀÌ»óÀ¸·Î ÀÌÀÚ°üÀÌ ¸·È÷°Å³ª ÀÌÀÚÀÇ ±â´ÉÀÌ ¶³¾îÁ®¼ ¼ÒÈÀÇ Àå¾Ö¸¦ ÀÏÀ¸Å°±âµµ ÇÑ´Ù. À¯Å°迡 ¸¹À¸¸ç ¿ì¸®³ª¶ó¿¡´Â ¾ÆÁÖ µå¹°´Ù. |
||
| ¿µ¹® | fibrosis | ÇÑ±Û | ¼¶À¯Áõ, ¼¶À¯È |
|---|---|---|---|
| ¼³¸í | ¾Æ±³Áú¼¶À¯¸¦ Çü¼ºÇÏ´Â ¼¶À¯Á¶Á÷ÀÇ Áõ½ÄÀ¸·Î ¸öÀÇ ½ÇÁú¼¼Æ÷ÀÇ ±«»ç³ª ¼Õ»ó¿¡ ÀÌ¾î¼ ³ªÅ¸³ª´Â °æ¿ì°¡ º¸ÅëÀÌ´Ù. µÎ ´Ü°è, Áï ¼Õ»óºÎÀ§¿¡¼ ¼¶À¯¸ð¼¼Æ÷ÀÇ ÀÌÁÖ¿Í Áõ½Ä, ±×¸®°í ¼¶À¯¸ð¼¼Æ÷¿¡ ÀÇÇÑ ¼¼Æ÷ÀÇ ¹ÙÅÁÁú ÃàÀûÀ¸·Î ÁøÇàµÈ´Ù. ÇǺÎÀÇ °æ¿ì ÁøÇdz» ¼¶À¯¸ð¼¼Æ÷ÀÇ Áõ½Ä°ú ¾Æ±³Áú ¼¶À¯ÀÇ Áõ½ÄÀÌ ÀÖ´Â °æ¿ì¸¦ ¼¶À¯È, °ÅÀÇ ¾Æ±³Áú ¼¶À¯·Î¸¸ ±¸¼ºµÇ´Â °æ¿ì¸¦ °æÈ¶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | chronic obstructive pulmonary disease | ÇÑ±Û | ¸¸¼ºÆó¼âÆóº´ |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö õ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù. ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í ÀÌ·Î ÀÎÇØ¼ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀÌ Çª¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³´Ù. Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇÏ°Ô ÆìÁö´Â °ÍÀ» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù. ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀÎ Æó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | pulmonary function tests | ÇÑ±Û | Æó±â´É °Ë»ç |
|---|---|---|---|
| ¼³¸í | ¿©·¯ °¡Áö ±â±¸¸¦ ÀÌ¿ëÇØ Æó¿ëÀû ¹× ÇãÆÄÀÇ È®»ê´ÉÀ» ¾Ë¾Æº¸´Â °Ë»ç·Î ¸» ±×´ë·Î ÇãÆÄÀÇ ±â´ÉÀ» ÃøÁ¤ÇÏ´Â °Ë»çÀÌ´Ù. |
||
| ¿µ¹® | pulmonary circulation | ÇÑ±Û | Æó¼øÈ¯ |
|---|---|---|---|
| ¼³¸í | Àü½Å¼øÈ¯À» °ÅÄ£ »ê¼ÒºÐ¾ÐÀÌ ³·Àº Á¤¸ÆÇ÷ÀÌ ¿À¸¥½É¹æÀ¸·Î µé¾î¿Í ¿À¸¥½É½ÇÀ» °ÅÃÄ Æóµ¿¸ÆÀ» ÅëÇÏ¿© Æó·Î °¡¼ °¡½º ±³È¯À» ÇÑ ÈÄ, »ê¼ÒºÐ¾ÐÀÌ ³ôÀº µ¿¸ÆÇ÷ÀÌ µÇ¾î ÆóÁ¤¸ÆÀ» Ÿ°í ´Ù½Ã Á½ɹæÀ¸·Î µ¹¾Æ¿À´Â Ç÷¾×ÀÇ ¼øÈ¯°úÁ¤À» À̸£´Â ¸»ÀÌ´Ù. |
||
| CFF | critical flicker fusion [test]; critical fusion frequency; cystic fibrosis factor; Cystic Fibrosis F... |
|---|---|
| CFP | chronic false positive; Clinical Fellowship Program; cyclophosphamide, fluorouracil, prednisone; cys... |
| MF | 1) Myelo-Fibrosis = Agnogenic Myeloid Metaplasia with Myelo-F... |
| IPF | idiopathic pulmonary fibrosis; infection-potentiating factor; interstitial pulmonary fibrosis |
| CF | 1) Cystic Fibrosis 2) Complement Fixing antibody 3) Conver... |
| CFTR | Cystic Fibrosis Transmembrane Conductance Regulator |
|---|---|
| CFTR | Cystic Fibrosis Transmembrane Conductance Regulator Gene |
| CFTR | Cystic Fibrosis Transmembrane Regulator |
| CFP | Cystic fibrosis protein |
| CFTR | cystic fibrosis transmembrane conductance regulator protein |
pulmonary pleura
| cystic fibrosis | <chest medicine> A generalised disorder of infants, children and young adults, in which there is widespread dysfunction of the exocrine glands, characterised by signs of chronic pulmonary disease (due to excess mucus production in the respiratory tract), pancreatic deficiency, abnormally high levels of electrolytes in the sweat and occasionally by biliary cirrhosis. There is an ineffective immunologic defense against bacteria in the lungs. Pathologically, the pancreas shows obstruction of the pancreatic ducts by amorphous eosinophilic concretions, with consequent deficiency of pancreatic enzymes, resulting in steatorrhoea and azotorrhoea and intestinal malabsorption. The degree of involvement of organs and glandular systems may vary greatly, with consequent variations in the clinical picture. Inheritance: autosomal recessive. (13 Nov 1997) |
|---|---|
| cystic fibrosis antigen | Now known to be MRP 8. See: calgranulins. (18 Nov 1997) |
| cystic fibrosis transmembrane conductance regulator | Gene believed to be defective in cystic fibrosis. Gene encodes a chloride channel, homologous to a family of proteins that actively transport small solutes in an ATP dependent manner (ABC transporters). The regulator protein is a protein which is embedded in the cell membrane and acts as a channel for certain ions to be transported into or out of the cell. The disease cystic fibrosis is caused by a defect in the gene for this protein. (09 Oct 1997) |
| pulmonary fibrosis | Chronic inflammation and progressive fibrosis of the pulmonary alveolar walls, with steadily progressive dyspnea, resulting finally in death from oxygen lack or right heart failure. (12 Dec 1998) |
| diffuse interstitial pulmonary fibrosis | This represents a group of pulmonary disorders (lower respiratory tract) that leads to a functional loss in the alveolar air sacs and a compromise in the diffusion of oxygen from air to blood. There is widespread inflammation and scar tissue (fibrosis) formation within the lung. The causes are varied and include: inorganic and organic dusts, gases, fumes, vapors, infections, radiation, medications, coal dust, silicosis and byssinosis. When the cause is not identifiable it is referred to as idiopathic diffuse interstitial pulmonary fibrosis (27 Sep 1997) |
| idiopathic pulmonary fibrosis | <radiology> Aka: usual interstitial pneumonia (UIP), 5-6th decade; M:F = 1:1, clubbing of fingers (83%), lymphocytosis on lavage, increased occurence of bronchogenic CA, average survival of 4-6 years; 87% mortality CXR findings: occasional ground glass pattern in early stage of alveolitis, diffuse reticulations (60%) predominantly at bases, honeycombing, pleural effusion (4%); pleural thickening (6%), pneumothorax in 7% (late stage), progressive volume loss see: interstitial pulmonary fibrosis (12 Dec 1998) |
| interstitial pulmonary fibrosis | <radiology> Idiopathic, idiopathic pulmonary fibrosis (AKA: usual interstitial pneumonitis), Hamman-Rich syndrome (rapidly progressive), drug-related, collagen-vascular disease, rheumatoid lung disease, scleroderma (12 Dec 1998) |
| amyloidosis: bone manifestations | <radiology> Joint pain without radiographic findings, osteoporosis, especially in axial skeleton, lytic lesions that destroy cortex and invade soft tissue, wrist, scaphoid and lunate lesions that may extend into the carpal tunnel, inducing the classic complaints of carpal tunnel syndrome amyloid arthropathy Differential diagnosis: pigmented villonodular synovitis, synovial chondromatosis, rheumatoid arthritis, TB (12 Dec 1998) |
| amyloidosis: gastrointestinal manifestations | <radiology> Oesophagus, loss of peristalsis, megaesophagus, stomach, small and rigid (simulate linitis plastica), effaced rugal pattern, diminished/absent peristalsis, may be localised to antrum, amyloidoma: well defined submucosal mass, small bowel, diffuse form (more common), diffuse, uniform thickening of valvulae conniventes, broadened flat undulated mucosal folds (mucosal atrophy), jejunalization of ileum, impaired motility, small bowel dilatation, localised form: multiple small deposits; associated with pseudoobstruction, colon, psudopolyps (12 Dec 1998) |
| rheumatoid arthritis: joint manifestations | <radiology> Early signs: fusiform periarticular soft tissue swelling (result of effusion), regional osteoporosis (disuse and local hyperaemia), widened joint space, marginal and central bone erosion (base of 4th proximal phalanx most common), change in ulnar styloid and distal radioulnar joint, atlantoaxial dislocation, giant synovial cysts late signs: flexion/extension contractures with ulnar subluxation/dislocation, destruction/fusion of joints, elevation of humeral heads (tear/atrophy of rotator cuff), resorption of distal clavicle, erosion of superior margins of posterior portions of 3-5th ribs, destruction/narrowing of disc spaces, destruction of zygapophyseal joints without osteophyte formation, resorption of spinous process, protrusio acetabuli (from osteoporosis) (12 Dec 1998) |
| crohn disease: extraintestinal manifestations | <radiology> Fatty liver, gallstones (28-34%), risk 3-5X higher than expected, secondary to malabsorption of bile salts in terminal ileum, correlation with length of diseased ileum and duration of disease, sclerosing cholangitis, bile duct carcinoma, amyloidosis, urolithiasis: oxalate/uric acid stones, migratory arthritis (5-20%), sacroilitis, ankylosing spondylitis, erythema nodosum, uveitis see: Crohn disease (12 Dec 1998) |
| sickle cell anaemia: bone manifestations | <radiology> 8-13% of blacks carry sickling factor, symptoms: chronic ulcers, pain crises, many infections, priapism X-ray findings: deossification due to marrow hyperplasia, decreased bone density in skull with widened diploe, H-shaped vertebrae or fish vertebrae, rib notching, thrombosis and infarction, avascular necrosis, especially femoral head, periosteal treatmentn (bone within bone), secondary osteomyelitis, Staph. Aureus greater than Salmonella, dactylitis = hand foot syndrome, growth effects, bone shortening secondary to diminished blood supply, death less than 40y (12 Dec 1998) |
| skin manifestations | Dermatologic disorders attendant upon non-dermatologic disease or injury. (12 Dec 1998) |
| skin manifestations of GI disease | <radiology> Pancreatic carcinoma . . . . . . . . Thrombophlebitis migrans, glucagonoma . . . . . . . . . Migratory necrolytic erythema, IBD . . . . . . . . . . . . . . . Pyoderma gangrenosum, sprue / coeliac disease. . . . Dermatitis herpetiformis, Whipple disease . . . . . . . Pigmentation, primary biliary cirrhosis . . . . Exanthemasma, hepatic cirrhosis . . . . . . . . Spider angiomata (12 Dec 1998) |
| neurologic manifestations | Neurologic disorders attendant upon non-neurologic disease or injury. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|